Top Markets
Coin of the day
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
株式のランク #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
株価
$0.30780727
時価総額
$94.19M
変化(1日)
-0.19%
変化(1年)
-34.73%
FR
取引 Sensorion SA (ALSEN)

カテゴリー

Sensorion SA(ALSEN)の株式分割履歴
Sensorion SA株(シンボル:ALSEN)は合計で0回の株式分割を実施しました。
最新の株式分割はJul 13, 2026に行われました。
Jul 13, 2026より前に購入されたALSEN株は、現在0ALSEN株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
5 x199
DK
1 x2
US
0 -
US
0 -
BE
0 -
NL